Aprea Therapeutics (NASDAQ:APRE) Price Target Lowered to $1.20 at HC Wainwright

Aprea Therapeutics (NASDAQ:APRE) had its price target reduced by HC Wainwright from $4.00 to $1.20 in a report published on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other brokerages have also recently commented on APRE. Zacks Research raised shares of Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, February 16th. Wedbush dropped their price target on Aprea Therapeutics from $11.00 to $7.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Aprea Therapeutics has a consensus rating of “Hold” and an average target price of $4.10.

Aprea Therapeutics Trading Up 3.2%

Shares of APRE opened at $0.76 on Tuesday. The company’s 50 day simple moving average is $0.76 and its 200-day simple moving average is $1.05. The firm has a market cap of $8.74 million, a PE ratio of -0.39 and a beta of 1.42. Aprea Therapeutics has a 12-month low of $0.55 and a 12-month high of $2.30.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.06. Aprea Therapeutics had a negative net margin of 4,405.59% and a negative return on equity of 96.33%. The firm had revenue of $0.00 million during the quarter. As a group, equities research analysts forecast that Aprea Therapeutics will post -2.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aprea Therapeutics stock. DRW Securities LLC acquired a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 120,651 shares of the company’s stock, valued at approximately $103,000. DRW Securities LLC owned approximately 1.73% of Aprea Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.